Peptibase
FDA ApprovedWeight Loss

Orforglipron for Weight Loss

Research, mechanism, dosing, and effectiveness of Orforglipron for weight loss.

Quick Answer

Orforglipron is an oral non-peptide GLP-1 agonist in Phase 3 trials.

Evidence Level

Human Trials

Typical Dose

Under clinical investigation (up to 45 mg daily)

Results Timeline

Weight loss in trial participants

FDA Status

FDA Approved

How Orforglipron Works for Weight Loss

Small molecule GLP-1 receptor agonist without peptide limitations.

About Weight Loss

Reduction of body fat and overall body weight through appetite control and metabolic enhancement.

Research Evidence

ATTAIN-1 Phase 3 results showed significant weight loss. ATTAIN-MAINTAIN showed it helps maintain weight after injectable GLP-1 treatment. NDA submitted late 2025. Selected for FDA National Priority Voucher program but review was delayed to April 2026. FDA approved Foundayo (orforglipron) on April 1, 2026 under the National Priority Voucher Program — the fastest new molecular entity approval since 2002. It is the first oral non-peptide GLP-1 receptor agonist approved for chronic weight management.

Clinical Status:FDA Approved (April 2026) - Obesity/overweight with comorbidities. Brand name: Foundayo. First oral GLP-1 for weight loss with no food/water restrictions.

Dosing for Weight Loss

Recommended Dose

Under clinical investigation (up to 45 mg daily)

Frequency

See research protocols

Administration

Oral tablet daily

Duration

Long-term use expected

Note: Not yet FDA approved (decision expected April 2026). If approved, Lilly has announced LillyDirect pricing: $149-$399/month self-pay depending on dose.

What to Expect

Week 1-2

Initial adjustment period. Some users may notice subtle changes.

Week 3-4

Early benefits often become noticeable. Continue consistent use.

Week 5-8

Most users report meaningful improvements by this point.

2-3 Months

Full effects typically realized. Reassess and adjust as needed.

Possible Side Effects

Not everyone experiences these. Individual responses vary.

  • •Diarrhea (19-26%)
  • •Nausea (13-18%)
  • •Vomiting
  • •GI events mild-moderate
  • •Pulse increase
  • •Investigational - not yet approved

Frequently Asked Questions

Does Orforglipron help with weight loss?

Orforglipron is an oral non-peptide GLP-1 agonist in Phase 3 trials.

How does Orforglipron work for weight loss?

Small molecule GLP-1 receptor agonist without peptide limitations....

What dose of Orforglipron should I use for weight loss?

Under clinical investigation (up to 45 mg daily)

How long until I see results?

Weight loss in trial participants

Other Peptides for Weight Loss

These peptides are also researched for weight loss.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Dulaglutide

FDA

An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.

View Full Orforglipron ProfileHow to Use Orforglipron